WO2002062767A1 - Nouveaux derives de quinazoline - Google Patents

Nouveaux derives de quinazoline Download PDF

Info

Publication number
WO2002062767A1
WO2002062767A1 PCT/JP2002/001045 JP0201045W WO02062767A1 WO 2002062767 A1 WO2002062767 A1 WO 2002062767A1 JP 0201045 W JP0201045 W JP 0201045W WO 02062767 A1 WO02062767 A1 WO 02062767A1
Authority
WO
WIPO (PCT)
Prior art keywords
hydrogen
quinazoline derivatives
general formula
following general
novel quinazoline
Prior art date
Application number
PCT/JP2002/001045
Other languages
English (en)
Japanese (ja)
Inventor
Sumitsugu Kisanuki
Hideyuki Tomizawa
Yoshiaki Isobe
Original Assignee
Sumitomo Pharmaceuticals Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharmaceuticals Company, Limited filed Critical Sumitomo Pharmaceuticals Company, Limited
Publication of WO2002062767A1 publication Critical patent/WO2002062767A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Compositions médicinales servant à prévenir ou à traiter des maladies inflammatoires provoquées par un ADN bactérien, et contenant en tant qu'ingrédient actif des dérivés de quinazoline représentés par la formule suivante (I), dans laquelle R?5, R6, R7 et R8¿ représentent chacun hydrogène; R2 représente aryle, hétéroaryle; n est 0 ou 1 et X représente un groupe de formules suivantes (a) ou (b), dans lesquelles P représente alkylène C¿2-6?; R?9 et R10¿ représentent hydrogène; Y représente CHR11, dans laquelle R11 représente hydrogène et Z représente hydrogène.
PCT/JP2002/001045 2001-02-07 2002-02-07 Nouveaux derives de quinazoline WO2002062767A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001030973 2001-02-07
JP2001-30973 2001-02-07

Publications (1)

Publication Number Publication Date
WO2002062767A1 true WO2002062767A1 (fr) 2002-08-15

Family

ID=18895118

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/001045 WO2002062767A1 (fr) 2001-02-07 2002-02-07 Nouveaux derives de quinazoline

Country Status (1)

Country Link
WO (1) WO2002062767A1 (fr)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006523238A (ja) * 2003-04-09 2006-10-12 エクセリクシス， インク． Ｔｉｅ−２モジュレータと使用方法
JP2007524615A (ja) * 2003-06-20 2007-08-30 コーリー ファーマシューティカル ゲーエムベーハー 低分子トール様レセプター（ｔｌｒ）アンタゴニスト
WO2007117161A1 (fr) * 2006-04-07 2007-10-18 Auckland Uniservices Limited Azines à noyau condensées et substituées et leur utilisation pour une thérapie anti-cancéreuse
JP2008526734A (ja) * 2004-12-31 2008-07-24 エスケー ケミカルズ カンパニー リミテッド 糖尿及び肥満治療予防に有効なキナゾリン誘導体
US7632840B2 (en) 2004-02-03 2009-12-15 Astrazeneca Ab Quinazoline compounds for the treatment of hyperproliferative disorders
US7838530B2 (en) 2003-09-25 2010-11-23 Astrazeneca Ab Quinazoline derivatives as antiproliferative agents
US7910731B2 (en) 2002-03-30 2011-03-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US7998949B2 (en) 2007-02-06 2011-08-16 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
US8088782B2 (en) 2008-05-13 2012-01-03 Astrazeneca Ab Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate form A
WO2012046207A1 (fr) * 2010-10-08 2012-04-12 Paraco Technology Limited Composés azines à noyaux condensés substitués, antiparasitaires
WO2013003586A1 (fr) 2011-06-29 2013-01-03 Otsuka Pharmaceutical Co., Ltd. Quinazolines comme composés thérapeutiques et procédés d'utilisation s'y rapportant
US8399461B2 (en) 2006-11-10 2013-03-19 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for production of same
US8497369B2 (en) 2008-02-07 2013-07-30 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
US8507507B2 (en) 2009-10-22 2013-08-13 Gilead Sciences, Inc. Modulators of toll-like receptors
US8575184B2 (en) 2009-09-03 2013-11-05 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
US8648191B2 (en) 2008-08-08 2014-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
JP2014141522A (ja) * 2008-03-13 2014-08-07 Guangzhou Institute Of Biomedicine And Health Chinese Academy Of Sciences エストロゲン関連受容体モジュレータ化合物及びその使用
WO2015019121A1 (fr) * 2013-08-09 2015-02-12 Vichem Chemie Kutató Kft. Dérivés styryl quinazoline utilisés comme agents pharmaceutiquement actifs
US9073890B2 (en) 2009-12-31 2015-07-07 Otsuka Pharmaceutical Co., Ltd. Therapeutic compounds and related methods of use
CN111253325A (zh) * 2020-03-25 2020-06-09 广州大学 氨基喹唑啉芳基哌嗪类化合物及其药物组合物和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06192235A (ja) * 1992-07-15 1994-07-12 Ono Pharmaceut Co Ltd ４−アミノキナゾリン誘導体、その製造方法およびそれを含有する医薬品
WO1999009986A1 (fr) * 1997-08-22 1999-03-04 Kyowa Hakko Kogyo Co., Ltd. Derives de 4-aminoquinazoline
DE19756388A1 (de) * 1997-12-18 1999-06-24 Hoechst Marion Roussel De Gmbh Substituierte 2-Aryl-4-amino-chinazoline

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06192235A (ja) * 1992-07-15 1994-07-12 Ono Pharmaceut Co Ltd ４−アミノキナゾリン誘導体、その製造方法およびそれを含有する医薬品
WO1999009986A1 (fr) * 1997-08-22 1999-03-04 Kyowa Hakko Kogyo Co., Ltd. Derives de 4-aminoquinazoline
DE19756388A1 (de) * 1997-12-18 1999-06-24 Hoechst Marion Roussel De Gmbh Substituierte 2-Aryl-4-amino-chinazoline

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8343982B2 (en) 2002-03-30 2013-01-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocyclic compounds pharmaceutical compositions containing these compounds, their use and process for preparing the same
US7910731B2 (en) 2002-03-30 2011-03-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
JP2006523238A (ja) * 2003-04-09 2006-10-12 エクセリクシス， インク． Ｔｉｅ−２モジュレータと使用方法
JP4895806B2 (ja) * 2003-04-09 2012-03-14 エクセリクシス， インク． Ｔｉｅ−２モジュレータと使用方法
JP2007524615A (ja) * 2003-06-20 2007-08-30 コーリー ファーマシューティカル ゲーエムベーハー 低分子トール様レセプター（ｔｌｒ）アンタゴニスト
US7838530B2 (en) 2003-09-25 2010-11-23 Astrazeneca Ab Quinazoline derivatives as antiproliferative agents
US7632840B2 (en) 2004-02-03 2009-12-15 Astrazeneca Ab Quinazoline compounds for the treatment of hyperproliferative disorders
JP2008526734A (ja) * 2004-12-31 2008-07-24 エスケー ケミカルズ カンパニー リミテッド 糖尿及び肥満治療予防に有効なキナゾリン誘導体
WO2007117161A1 (fr) * 2006-04-07 2007-10-18 Auckland Uniservices Limited Azines à noyau condensées et substituées et leur utilisation pour une thérapie anti-cancéreuse
JP2009533338A (ja) * 2006-04-07 2009-09-17 オークランド ユニサーヴィスィズ リミテッド 置換環縮合アジンおよび癌治療におけるそれらの使用
US8399461B2 (en) 2006-11-10 2013-03-19 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for production of same
US7998949B2 (en) 2007-02-06 2011-08-16 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
US8772298B2 (en) 2008-02-07 2014-07-08 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
US8497369B2 (en) 2008-02-07 2013-07-30 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
JP2014141522A (ja) * 2008-03-13 2014-08-07 Guangzhou Institute Of Biomedicine And Health Chinese Academy Of Sciences エストロゲン関連受容体モジュレータ化合物及びその使用
US8088782B2 (en) 2008-05-13 2012-01-03 Astrazeneca Ab Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate form A
US8648191B2 (en) 2008-08-08 2014-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
US10676460B2 (en) 2009-09-03 2020-06-09 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
US11008306B2 (en) 2009-09-03 2021-05-18 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
US8575184B2 (en) 2009-09-03 2013-11-05 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
US9458114B2 (en) 2009-09-03 2016-10-04 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
US10214511B2 (en) 2009-09-03 2019-02-26 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
US9822096B2 (en) 2009-09-03 2017-11-21 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
US8507507B2 (en) 2009-10-22 2013-08-13 Gilead Sciences, Inc. Modulators of toll-like receptors
US9161934B2 (en) 2009-10-22 2015-10-20 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
US8962652B2 (en) 2009-10-22 2015-02-24 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
EP3056207A1 (fr) 2009-12-31 2016-08-17 Otsuka Pharmaceutical Co., Ltd. Composés thérapeutiques et procédés d'utilisation associés
US9073890B2 (en) 2009-12-31 2015-07-07 Otsuka Pharmaceutical Co., Ltd. Therapeutic compounds and related methods of use
US9630947B2 (en) 2009-12-31 2017-04-25 Otsuka Pharmaceutical Co., Ltd. Therapeutic compounds and related methods of use
WO2012046207A1 (fr) * 2010-10-08 2012-04-12 Paraco Technology Limited Composés azines à noyaux condensés substitués, antiparasitaires
WO2013003586A1 (fr) 2011-06-29 2013-01-03 Otsuka Pharmaceutical Co., Ltd. Quinazolines comme composés thérapeutiques et procédés d'utilisation s'y rapportant
US9951029B2 (en) 2013-08-09 2018-04-24 Vichem Chemie Kutató Kft. Styryl quinazoline derivatives as pharmaceutically active agents
WO2015019121A1 (fr) * 2013-08-09 2015-02-12 Vichem Chemie Kutató Kft. Dérivés styryl quinazoline utilisés comme agents pharmaceutiquement actifs
CN111253325A (zh) * 2020-03-25 2020-06-09 广州大学 氨基喹唑啉芳基哌嗪类化合物及其药物组合物和应用

Similar Documents

Publication Publication Date Title
WO2002062767A1 (fr) Nouveaux derives de quinazoline
ES2187473T3 (es) Triarylimidazoles.
TR200200749T2 (tr) Kinazolin bileşikleri ve bunları içeren farmasötik bileşikler.
WO2001014376A8 (fr) Nouveaux composes spiro
DK0750618T3 (da) Oxazolidinonderivater og farmaceutiske præparater indeholdende dem
WO2002024686A3 (fr) Derives de la quinoleine et de la quinazoline 6-heterocyclylmethyle inhibiteurs de la farnesyle transferase
CA2414095A1 (fr) Nouveaux composes
NO992821L (no) Ketobenzamider som calpain-inhibitorer
MY137774A (en) Acetylene derivatives having mglur5 antagonistic activity
SE9904652D0 (sv) Novel Compounds
NO996108L (no) 9-oksinerytromycinderivater
DE60118225D1 (de) Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
EP1396493A4 (fr) Composes heterocycliques
NO20052182L (no) Nye forbindelser
CA2336412A1 (fr) Medicament pour le traitement du diabete
EP1702917A4 (fr) Derive d'amide et medicament
ATE398117T1 (de) Verbindungen mit antibakteriellen und antiparasitischen eigenschaften
EP0765865A4 (fr) Compose de 2-acylaminopropanol et composition medicinale
WO2003051274A3 (fr) Derives de la benzodiazepine, leur preparation et leur utilisation
WO2003053971A8 (fr) Antiviraux a base de pyridoquinoxaline
WO2002024697A1 (fr) Composes spiro et inhibiteurs de molecules d'adhesion contenant ces composes comme ingredient actif
SE0101038D0 (sv) Novel compounds
YU33202A (sh) Jedinjenja o-etar oksima i fungicidi za primenu u zemljoradnji i vrtlarstvu
EP1295880A4 (fr) Derives imidazole ou sels de ces derniers, et medicaments contenant les derives ou les sels
WO2001062709A3 (fr) Utilisation de derives de 2-phenylene diamine pour le traitement d'infections

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP NZ US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP